tradingkey.logo
tradingkey.logo
Search

Shattuck Labs Inc

STTK
Add to Watchlist
6.260USD
-0.410-6.15%
Close 05/15, 16:00ETQuotes delayed by 15 min
473.14MMarket Cap
LossP/E TTM

Shattuck Labs Inc

6.260
-0.410-6.15%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Shattuck Labs Inc

Currency: USD Updated: 2026-05-15

Key Insights

Shattuck Labs Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Shattuck Labs Inc's Score

Industry at a Glance

Industry Ranking
89 / 382
Overall Ranking
208 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Shattuck Labs Inc Highlights

StrengthsRisks
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.00M.
Undervalued
The company’s latest PE is -11.10, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.41M shares, increasing 16.19% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 36.93K shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
13.000
Target Price
+94.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Shattuck Labs Inc is 7.66, ranking 70 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
7.66
Change
0

Financials

9.61

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.01

Operational Efficiency

3.14

Growth Potential

10.00

Shareholder Returns

7.54

Shattuck Labs Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Shattuck Labs Inc is 6.80, ranking 209 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.10, which is -95.24% below the recent high of -0.53 and -12.14% above the recent low of -12.44.

Score

Industry at a Glance

Previous score
6.80
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 89/382
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Shattuck Labs Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 6.00 and a low of 2.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
13.000
Target Price
+94.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Shattuck Labs Inc
STTK
8
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Shattuck Labs Inc is 6.80, ranking 149 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.74 and the support level at 5.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.10
Change
-0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.241
Neutral
RSI(14)
41.026
Neutral
STOCH(KDJ)(9,3,3)
34.846
Neutral
ATR(14)
0.586
High Vlolatility
CCI(14)
-108.306
Sell
Williams %R
83.688
Oversold
TRIX(12,20)
-0.169
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
6.664
Sell
MA10
6.657
Sell
MA20
7.091
Sell
MA50
6.693
Sell
MA100
5.380
Buy
MA200
3.642
Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Shattuck Labs Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.78%, representing a quarter-over-quarter increase of 15.86%. The largest institutional shareholder is PRFDX, holding a total of 1.93M shares, representing 2.51% of shares outstanding, with 42474.58% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
T. Rowe Price Investment Management, Inc.
7.37M
+444.29%
OrbiMed Advisors, LLC
6.31M
--
Adage Capital Management, L.P.
6.31M
--
Redmile Group, LLC
5.54M
--
NEXTBio Capital Management LP
3.15M
--
Houghton Capital Holdings, LLC
2.61M
--
Prosight Capital
2.38M
-56.31%
T. Rowe Price Associates, Inc.
Star Investors
1.93M
+5515.57%
The Clark Estates Inc.
1.48M
--
1
2

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Shattuck Labs Inc is 2.30, ranking 226 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.30
Change
0
Beta vs S&P 500 index
1.12
VaR
+8.14%
240-Day Maximum Drawdown
+38.49%
240-Day Volatility
+105.89%

Return

Best Daily Return
60 days
+17.45%
120 days
+20.60%
5 years
+130.33%
Worst Daily Return
60 days
-6.49%
120 days
-7.27%
5 years
-44.99%
Sharpe Ratio
60 days
+2.93
120 days
+3.60
5 years
+0.31

Risk Assessment

Maximum Drawdown
240 days
+38.49%
3 years
+93.45%
5 years
+96.61%
Return-to-Drawdown Ratio
240 days
+12.97
3 years
+0.35
5 years
-0.14
Skewness
240 days
+1.21
3 years
+5.41
5 years
+5.27

Volatility

Realised Volatility
240 days
+105.89%
5 years
+121.21%
Standardised True Range
240 days
+4.25%
5 years
+6.13%
Downside Risk-Adjusted Return
120 days
+855.47%
240 days
+855.47%
Maximum Daily Upside Volatility
60 days
+54.97%
Maximum Daily Downside Volatility
60 days
+38.94%

Liquidity

Average Turnover Rate
60 days
+1.21%
120 days
+1.19%
5 years
--
Turnover Deviation
20 days
-18.82%
60 days
-12.27%
120 days
-14.24%

Peer Comparison

Biotechnology & Medical Research
Shattuck Labs Inc
Shattuck Labs Inc
STTK
6.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI